Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, COMPARING IVERMECTIN CREAM 1% (ZYDUS WORLDWIDE DMCC) TO SOOLANTRA® (GALDERMA LABORATORIES, L.P.) AND BOTH ACTIVE TREATMENTS TO A PLACEBO CONTROL IN THE TREATMENT OF MODERATE TO SEVERE FACIAL ROSACEA

NCT04106726 is registered in ClinicalTrials.gov with Zydus Worldwide DMCC as lead sponsor.

NCT NCT04106726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04106726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, COMPARING IVERMECTIN CREAM 1% (ZYDUS WORLDWIDE DMCC) TO SOOLANTRA® (GALDERMA LABORATORIES, L.P.) AND BOTH ACTIVE TREATMENTS TO A PLACEBO CONTROL IN THE TREATMENT OF MODERATE TO SEVERE FACIAL ROSACEA
Lead sponsor
Zydus Worldwide DMCC
Phase
Phase 3
Overall status
Completed
Start date
October 17, 2019
Completion date
August 4, 2020
Enrollment
525 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

facial rosacea